Literature DB >> 9443938

Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases.

A Saxena1, Y Ashani, L Raveh, D Stevenson, T Patel, B P Doctor.   

Abstract

To understand the role of glycosylation in the circulation of cholinesterases, we compared the mean residence time of five tissue-derived and two recombinant cholinesterases (injected intravenously in mice) with their oligosaccharide profiles. Monosaccharide composition analysis revealed differences in the total carbohydrate, galactose, and sialic acid contents. The molar ratio of sialic acid to galactose residues on tetrameric human serum butyrylcholinesterase, recombinant human butyrylcholinesterase, and recombinant mouse acetylcholinesterase was found to be approximately 1.0. For Torpedo californica acetylcholinesterase, monomeric and tetrameric fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase, this ratio was approximately 0.5. However, the circulatory stability of cholinesterases could not be correlated with the sialic acid-to-galactose ratio. Fractionation of the total pool of oligosaccharides obtained after neuraminidase digestion revealed one major oligosaccharide for human serum butyrylcholinesterase and three or four major oligosaccharides in other cholinesterases. The glycans of tetrameric forms of plasma cholinesterases (human serum butyrylcholinesterase, fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase) clearly demonstrated a reduced heterogeneity and higher maturity compared with glycans of monomeric fetal bovine serum acetylcholinesterase, dimeric tissue-derived T. californica acetylcholinesterase, and recombinant cholinesterases. T. californica acetylcholinesterase, recombinant cholinesterases, and monomeric fetal bovine serum acetylcholinesterase showed a distinctive shorter mean residence time (44-304 min) compared with tetrameric forms of plasma cholinesterases (1902-3206 min). Differences in the pharmacokinetic parameters of cholinesterases seem to be due to the combined effect of the molecular weight and charge- and size-based heterogeneity in glycans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443938     DOI: 10.1124/mol.53.1.112

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents.

Authors:  Brian C Geyer; Latha Kannan; Pierre-Emmanuel Garnaud; Clarence A Broomfield; C Linn Cadieux; Irene Cherni; Sean M Hodgins; Shane A Kasten; Karli Kelley; Jacquelyn Kilbourne; Zeke P Oliver; Tamara C Otto; Ian Puffenberger; Tony E Reeves; Neil Robbins; Ryan R Woods; Hermona Soreq; David E Lenz; Douglas M Cerasoli; Tsafrir S Mor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo.

Authors:  Denis G Ilyushin; Ivan V Smirnov; Alexey A Belogurov; Igor A Dyachenko; Tatiana Iu Zharmukhamedova; Tatjana I Novozhilova; Eugene A Bychikhin; Marina V Serebryakova; Oleg N Kharybin; Arkadii N Murashev; Konstantin A Anikienko; Eugene N Nikolaev; Natalia A Ponomarenko; Dmitry D Genkin; G Michael Blackburn; Patrick Masson; Alexander G Gabibov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

3.  Effect of human acetylcholinesterase subunit assembly on its circulatory residence.

Authors:  T Chitlaru; C Kronman; B Velan; A Shafferman
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

4.  Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity.

Authors:  O Cohen; C Kronman; T Chitlaru; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

5.  Amino-acid mutations to extend the biological half-life of a therapeutically valuable mutant of human butyrylcholinesterase.

Authors:  Lei Fang; Shurong Hou; Liu Xue; Fang Zheng; Chang-Guo Zhan
Journal:  Chem Biol Interact       Date:  2014-02-25       Impact factor: 5.192

6.  Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath.

Authors:  Tama Evron; Brian C Geyer; Irene Cherni; Mrinalini Muralidharan; Jacquelyn Kilbourne; Samuel P Fletcher; Hermona Soreq; Tsafrir S Mor
Journal:  FASEB J       Date:  2007-05-02       Impact factor: 5.191

7.  The proline-rich tetramerization peptides in equine serum butyrylcholinesterase.

Authors:  Kevser Biberoglu; Lawrence M Schopfer; Ozden Tacal; Oksana Lockridge
Journal:  FEBS J       Date:  2012-09-07       Impact factor: 5.542

8.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Authors:  T Chitlaru; C Kronman; M Zeevi; M Kam; A Harel; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

9.  Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation.

Authors:  Yongmei Pan; Jennifer L Muzyka; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2009-05-07       Impact factor: 2.991

10.  Hairy-root organ cultures for the production of human acetylcholinesterase.

Authors:  Ryan R Woods; Brian C Geyer; Tsafrir S Mor
Journal:  BMC Biotechnol       Date:  2008-12-23       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.